language_icon
EN
HI

Metropolis Healthcare Share price

METROPOLIS

528.8

10.50 (2.03%)
NSE
BSE
Last updated on 21 May, 2026 | 15:59 IST
Today's High

537.35

Today's Low

525.05

52 Week Low

400.40

52 Week High

600.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Metropolis Healthcare Chart

Metropolis Healthcare Share Key Metrics

Volume
4.36 L
Market Cap
10963.49 CR
LTQ@LTP
1@528.80
ATP
530.75
Var Margin
14.84 %
Circuit Range
414.65-621.95
Delivery %
52.09 %
Value
23.15 CR
ASM/GSM
No
Market Lot
1

Summary

Metropolis Healthcare share price is ₹528.8 as of 21 May, 2026. The stock Metropolis Healthcare intraday movement has stayed between ₹525.05 and ₹537.35, while on a 52-week basis,Metropolis Healthcare price 52 week high is ₹600.00 & its 52 week low is ₹400.40.
In terms of trading activity, Metropolis Healthcare has recorded a volume of 436186 shares, The Metropolis Healthcare has a market cap of ₹207327768 CR. The stock’s Average Traded Price (ATP) stands at ₹530.75, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹528.80.
Metropolis Healthcare operates within a circuit range of ₹414.65 – ₹621.95, with a Value of ₹23.15 CR. The Delivery Percentage for the day is 52.09%. Additionally, Metropolis Healthcare currently falls under the No framework, and trades with a market lot size of 1.

Metropolis Healthcare Fundamentals

View More
P/E Ratio

56.55

P/B Ratio

7.1

Div. Yield

0.24

Sector P/E

56.75

Sector P/B

-15.78

Sec. Div. Yield

0.19

Metropolis Healthcare Resistance and Support

Pivot 511.48

Resistance

First Resistance

527.26

Second Resistance

536.23

Third Resistance

552.01

Support

First Support

502.51

Second Support

486.73

Third Support

477.76

Metropolis Healthcare Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

48.87%

Mutual Fund

33.28%

Insurance

2.16%

Foreign Institutional Investors

10.43%

Domestic Institutional Investors

0.35%

Retail

4.91%

Others

0%

Total Promoters
MAR '26
48.87%

Metropolis Healthcare Corporate Actions

DateAgenda
2026-05-13Audited Results & Interim Dividend
2026-02-04Quarterly Results & Bonus issue
2025-11-04Quarterly Results & Interim Dividend
2025-08-07Quarterly Results
2025-05-13Audited Results
2025-02-04Quarterly Results

Metropolis Healthcare News

Metropolis Healthcare Limited

Metropolis Healthcare Ltd. reported strong Q4 FY26 and full-year FY26 performance, with group revenue up 23% and 23.6% respectively. The company targets 14-15% CAGR revenue growth and 27-28% group EBITDA margin over the next three years, driven by organic growth and strategic initiatives.
May 19 2026 19:05:00

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Metropolis Healthcare has made the audio recording of its Q4 FY26 earnings conference call available on its official website. This recording, from the call held on May 14, 2026, provides detailed discussions on the company's financial results for the quarter.
May 14 2026 16:05:00

Metropolis Healthcare sees strong Q4 performance driven by specialty and preventive testing push

Metropolis Healthcare reported a strong performance for Q4 FY26, with consolidated net profit increasing by 75% year-on-year to ₹51 crore and revenue from operations growing 23% to ₹425 crore. This robust growth was driven by higher patient volumes, increased test volumes, significant B2C and B2B revenue growth, and an expanded focus on specialty and preventive testing, leading to improved EBITDA margins.
May 14 2026 14:05:00

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Metropolis Healthcare reported strong Q4 FY26 unaudited consolidated financial results with revenue increasing 23% YoY to Rs.425 crore, and net profit soaring 75% YoY to Rs.51 crore, driven by robust demand and operational efficiencies.
May 13 2026 20:05:00

Metropolis Healthcare Limited

Metropolis Healthcare declared an interim dividend of Re. 1 per equity share for FY 2025-26. The record date for this dividend has been fixed as May 19, 2026, indicating shareholder eligibility.
May 13 2026 19:05:00

Metropolis Healthcare Ltd - 542650 - Corporate Action-Board approves Dividend

Metropolis Healthcare announced a 2nd interim dividend of ₹1 per equity share for FY26. The record date for this dividend is May 19, 2026, with payments expected within 30 days of the declaration.
May 13 2026 18:05:00

Metropolis Healthcare Ltd - 542650 - Board Meeting Outcome for The Meeting Held Today (May 13, 2026)

Metropolis Healthcare reported strong Q4 FY26 cons. results: revenue climbed 23% YoY to ₹424.68 Cr, and net profit increased 74% to ₹50.96 Cr. The board also declared a ₹1 interim dividend for FY26, with May 19, 2026, as the record date.
May 13 2026 18:05:00

Metropolis Healthcare Limited

Metropolis Healthcare's Board is scheduled to meet on May 13, 2026. The agenda includes considering and approving the audited annual financial results for the financial year ended March 2026 and declaring an interim dividend.
May 07 2026 18:05:00

Metropolis Healthcare Limited

Metropolis Healthcare's Board is scheduled to meet on May 13, 2026. The agenda includes considering the yearly audited standalone and consolidated financial results for FY26 and an interim dividend declaration.
May 07 2026 18:05:00

Metropolis Healthcare Ltd - 542650 - Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Declaration Of 2Nd Interim Dividend, If Any, For The Financial Year 2025-26

Metropolis Healthcare's board will convene on May 13, 2026, to review and approve the audited financial results for Q4 and the full fiscal year ended March 31, 2026. The board will also consider declaring a 2nd interim dividend for FY26.
May 07 2026 18:05:00
Read More

About Metropolis Healthcare

NSE : 9581  
BSE : 542650  
ISIN : INE112L01020  

Dr. Sushil Kanubhai Shah one of The Promoters commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai’s Hospital having Dr. Kanubhai M. Shah Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30 1981 onwards. In June 1989 upon death of Dr. Kanubhai M. Shah the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18 1995 Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20 1995 the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners in the name and style of Metropolis Lab. In January 1998 Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1 2002 the business of Metropolis Lab was transferred to Dr. V. K. Desai’s Hospital as a going concern. In May 2002 Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai’s Hospital was changed to Metropolis Health Services in November 2002. Further in April 2003 Ameera Sushil Shah Jaswanti Kanubhai Shah Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services.In July 2003 Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited (“MHSIPL”) under the Companies Act 1956. The name of MHSIPL was changed to Metropolis Health Services (India) Limited (“MHSIL”) pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company’ granted by RoC on March 1 2006. In January 2009 MHSIL amalgamated with Pathnet India Private Limited which was a wholly owned subsidiary of MHSIL. For details see “– Scheme of amalgamation between Pathnet India Private Limited and Metropolis Health Services (India) Limited Metro Home Health Services Private Limited Lister Metropolis Laboratory and Research Centre Private Limited Tripoli Path Lab Private Limited and Diwanchand Metropolis Diagnostics Services Private Limited”.Pathnet India Private Limited was incorporated at New Delhi as a private limited company under the Companies Act 1956 pursuant to the ‘Certificate of Incorporation’ granted by the Registrar of Companies N. C. T. of Delhi and Haryana on November 10 2000. The name of The Company was changed to Pathnet India Limited pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company’ granted by RoC on July 1 2009. The name of The Company was changed to Metropolis Healthcare Limited pursuant to a ‘Fresh Certificate of Incorporation Consequent upon Change of Name’ granted by RoC on September 23 2009. Major events and milestones of The Company :2002-First major acquisition by the Company of Sudharma2004-The Company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology India)2005-The Company received accreditation from The College of American Pathologists2006-Investment by The Western India Trustee and Executor Company in the Company-Acquisition of M/s. Lister Laboratory and Research Centre Private Limited in Chennai2007-Acquisition of Desai Clinical Laboratory in Surat2008-Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore2009-Scheme of Amalgamation 20092010-Investment by Foxcreek Investment Limited in the Company2011-Acquisition of LabOne in Raipur2012-Acquisition of Micron Laboratories in Mumbai-Acquisition of subsidiary in Kenya-Acquisition of Dr. Patel Pathology Laboratory Private Limited in Nashik-Incorporation of subsidiary in Mauritius2013-Acquisition of M/s. Ekopath Center-Pathology and Cytology Division in Guwahati-Establishment of GRL in Mumbai2014-Acquisition of subsidiary in Ghana2015-Investment by CA Lotus Investments in the Company-Incorporation of subsidiary in Uganda-Incorporation of branch office in Zambia2017-Acquisition of Sanjeevani Pathology Laboratory in Rajkot2018-Public-Private partnership agreement executed with National AIDS Control Organisation Government of India-Scheme of Amalgamation 2018-Incorporation of subsidiary in Tanzania  Awards achievements and certifications :2010-The Company was awarded the “Diagnostic Services Company of the Year” by Frost & Sullivan2012-The Company was felicitated for providing “Outstanding Quality Diagnostic Services” by HIV Congress 20122014-The Company was awarded the “Most Promising Brand” by the World Consulting and Research Corporation-The Company was awarded as a “Quality Brand” by Quality Brands India2015-The Company was awarded the “Best Diagnostic Company of the Year” at the National Awards for Excellence in Healthcare 2015-The Company was awarded the “Diagnostic Services Company of the Year” by the VCCircle Network-The Company was awarded for “Excellence in Productive Employment Creation” by Business Today2018-The Company was awarded for “Best in Health and Fitness” in the Digital Campaign Awards by LH Insights-The Company was awarded for “Excellence in Customer Service & Delivery” by Biotrains-The Company was awarded special jury mention for “Service Excellence (Diagnostic Centre)” by FICCI at the Healthcare Excellence Awards2018-2019-The Company was awarded “Iconic Pathology Lab Mumbai” by Midday Health & Wellness Icons

Read More

Metropolis Healthcare Management

NamePosition
Sushil ShahChairman Emeritus
Ameera ShahChairperson
View More

Metropolis Healthcare FAQs

The Buying Price of Metropolis Healthcare share is 528.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Metropolis Healthcare stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Metropolis Healthcare, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Metropolis Healthcare shares is 56.55. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Metropolis Healthcare shares is 7.1. Useful to assess the stock's value relative to its book value.

To assess Metropolis Healthcare’s valuation compare Sector P/E, P/B which are 56.75 & -15.78 with sector averages, along with growth rates and financial metrics.

The Market Cap of Metropolis Healthcare is 10963.49 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Metropolis Healthcare share price is 600.00 & 400.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Metropolis Healthcare belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost